MP AdVisors – MP Advisors

MP Group: Idiopathic Pulmonary Fibrosis (IPF)

Post published:May 1, 2025
Post category:Therapeutic Class

It’s a pleasure to share with you our latest report on Idiopathic Pulmonary Fibrosis (IPF)—a field rapidly evolving amidst unmet needs, increasing prevalence, and a surge in innovation. This report delivers a strategic view of the clinical, commercial, and R&D shifts shaping the IPF landscape, tailored for leaders driving decisions in respiratory and rare diseases. Key highlights of the presentation are: The evolving treatment paradigm beyond antifibrotics—toward targeted, multi-pathway, and regenerative therapies Strategic insights on Phase 2 & 3 assets—differentiation…

MP Group: Inflammatory Bowel Disease Therapy Area Landscape: Breaking New Ground in Treatment

Post published:November 6, 2024
Post category:Therapeutic Class

It is our pleasure to share with you our latest report on Inflammatory Bowel Disease Therapy Area Landscape: Breaking New Ground in Treatment. The report provides market and competitive analysis of evolving therapeutic landscape of IBD while anticipating how the future treatment paradigm is likely to evolve. Key Highlights of the Deck - Assessment of the evolving treatment paradigm: Explore the market trends and transition from conventional step-up approaches to a more aggressive top-down strategy Current landscape of targeted therapies: Insights into the…

Pharmaphorum: Digital twins in healthcare and drug discovery: From idea to success stories

Post published:August 29, 2024
Post category:Perspectives

The term "digital twins" has its origins in engineering and computer science, where it refers to a virtual replica of a physical object or system. Simply put, it is a sophisticated, dynamic, real-time digital representation of a physical entity created using advanced computational models. The sole purpose of these models is to simulate how an object or process would change under a specific scenario. The aerospace industry has been particularly successful in deploying digital twins, where real-time data is fed…

Biospectrum: How Deep Tech is Powering India’s Biopharma Future

Post published:June 5, 2024
Post category:Perspectives

Advancements in cutting-edge innovative technologies and the increasing availability of data have enabled various domains of the biotech and pharma industries to leverage resourceful approaches in driving progress, maintaining competitive advantage and accomplishing the ultimate goal of improved patient outcomes. Deep tech ventures, also referred to as hard tech as opposed to regular digital platforms, primarily focus on the fundamental core issues of a business. For India to become an ‘innovation hub’, with concerted transformative efforts of leaders and experts…

Outlook on AI and medical writing

Post published:June 27, 2022
Post category:Industry Themes

We are glad to present our outlook on ‘AI and medical writing’ that gives an overall perspective on the technological advancements in the medical writing industry. Medical writing is expected to be a $5B+ market with a ~10% CAGR in the next 5 years. However, the industry faces the challenge of high attrition rates and lack of resources. Inefficiencies are further fueled by limited use of automation to reuse content between different regulatory documents and publications as well as limited…

MP Group – Biosimilars Landscape – China and India

Post published:November 5, 2019
Post category:Industry Themes

As you are exploring biosimilar opportunities, we would be delighted to share our insights to help you advance your strategy. Our active work has enabled us to develop an in depth understanding of the global biosimilar opportunity, and many of our forecasts of the past decade are now being realized. In fact, that is why the title of the attached slide deck is “Creating a global biosimilars leadership - Combining complementary strengths of China and India” (Click here to download) Global…